Skip to content

Allergan Commemorates 60th Anniversary

Allergan Commemorates 60th Anniversary

On Friday, June 4th, Allergan executives and guests of the company visited the New York Stock Exchange to celebrate Allergan’s 60th anniversary. To mark the occasion, Allergan's Chairman of the Board and Chief Executive Officer David Pyott rang The Closing BellSM.

From our beginnings as an eye care company to our focus today on several medical specialties, Allergan is proud to celebrate 60 years of medical advances and proud to support the patients and physicians who rely on our products and the employees and communities in which we live and work.

Click the video link to see David Pyott ring The Closing Bell(SM)   >

Allergan Commemorates 60th Anniversary

Global in reach. Specialized in focus.

Allergan, Inc. is a multi-specialty health care company focused on discovering, developing and commercializing innovative pharmaceuticals, biologics and medical devices that enable people to live life to its greatest potential — to see more clearly, move more freely, express themselves more fully.

Our focus fosters deep engagement with medical specialists and we make it our business to listen closely to their needs so that together we can advance patient care. We combine this strategic focus with a diversified approach that enables us to follow our research and development into new specialty areas where unmet needs are significant.

In partnership with the medical community, we bring scientific excellence and rigor to deliver leading products that improve patient outcomes. And, we go above and beyond this to provide education and information, with the highest level of integrity, that helps patients to fully understand the choices available to them and make well-informed treatment decisions with their doctors. We know we are successful when doctors and patients place their trust in our products and our company, when our employees excel and when our efforts make a meaningful difference in the lives of the patients and communities we serve.

We are pleased to offer a number of leading products, including: BOTOX® (onabotulinumtoxinA), RESTASIS® (cyclosporine ophthalmic emulsion) 0.05%, LUMIGAN® (bimatoprost ophthalmic solution) 0.03%, BOTOX® Cosmetic (onabotulinumtoxinA), the JUVÉDERM® family of dermal fillers, and the LAP-BAND® Adjustable Gastric Banding System. Please look through this Web site for more information, including Important Safety Information, about these products and our full portfolio of products.

AGN NYSE
64.09 (0.51)
Volume 1,573,900

GLOBAL LOCATIONS

Learn about our worldwide locations.

  

NEWS & EVENTS

09.01.10Allergan Resolves United States Government Investigation of Past Sales and Marketing Practices Relating to Certain Therapeutic Uses of BOTOX(R)
08.31.10Allergan, Inc. Receives FDA Approval for LUMIGAN(R) 0.01% as First-Line Therapy Indicated for the Reduction of Elevated Intraocular Pressure in Glaucoma Patients
08.02.10Allergan Reports Second Quarter 2010 Operating Results
More news